Researchers discover mechanism of cell type-specific signaling in tumor development

April 7, 2009,

Mayo Clinic researchers have discovered the mechanisms behind two key checkpoints in cell growth and development — factors that may ultimately allow investigators to benchmark progression of tumor cells or stop them from further development. The findings appear in the current online issue of Developmental Cell.

The team led by Edward Leof, Ph.D., Mayo Clinic biochemist, demonstrated that p21-activated kinase 2 (PAK2), a key target for cancer growth and fibrotic tissue development, is activated in one type of tissue but not another. PAK2 is a downstream component of transforming growth factor beta (TGF-β) signaling in mesenchymal cells — those that make up connective tissues in the body, as well as blood and lymphatic vessels. However, TGF-β is unable to activate PAK2 in — those that make up external and internal linings, such as skin and the internal lining of many vessels.

"We decided to look at the factors that prevented PAK2 activation in epithelial cells," says Dr. Leof. "We found that a protein called Erbin, in cooperation with the NF2 suppressor Merlin, controls the outcome."

Erbin, the researchers found, controls the tumor suppressor gene Merlin. When Merlin is absent or mutated, the result is schwannoma, a form of tumor involving Schwann cells which make up the myelin sheath that covers nerves. Merlin has also been shown to play a part in causing melanoma, mesothelioma and possibly colorectal cancers.

The researchers showed that in epithelial cells, which have high levels of Erbin, the formation of an Erbin/Merlin complex prevents PAK2 activity following growth factor stimulation. In the absence of Erbin (or Merlin), however, TGF-β stimulates PAK2 activity in some epithelia, overcoming a critical checkpoint in tumor progression.

The findings are important, says Dr. Leof, because they delineate a process by which tumors might be formed and allow future researchers to pinpoint steps where interventions could not just gauge disease progression, but halt tumor growth. There is even the prospect of intervening before a tumor begins to form.

Source: Mayo Clinic (news : web)

Related Stories

Recommended for you

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.